Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
November 20 2020 - 8:00AM
Business Wire
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that a
pre-recorded fireside chat with President and Chief Executive
Officer Patrick J. Mahaffy will be available next week for replay
as part of the Piper Sandler 32nd Annual Healthcare Conference. The
virtual conference, which takes place November 30 to December 3,
2020, incorporates a library of pre-recorded fireside chat
presentations with presenting companies available on Monday,
November 23, 2020 at 10:00 a.m. Eastern time.
This conference is virtual and the pre-recorded presentation can
be accessed through the investor relations section of the Company’s
website at www.clovisoncology.com. The replay of the webcast will
be available on the Company’s website for 30 days. The presentation
was recorded on November 18, 2020, and statements made in the
presentation speak only as of such date. Clovis Oncology does not
undertake to update or revise any statements made therein.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on
acquiring, developing and commercializing innovative anti-cancer
agents in the U.S., Europe and additional international markets.
Clovis Oncology targets development programs at specific subsets of
cancer populations, and simultaneously develops, with partners,
diagnostic tools intended to direct a compound in development to
the population that is most likely to benefit from its use. Clovis
Oncology is headquartered in Boulder, Colorado; please visit
www.clovisoncology.com for more information, including additional
office locations in the U.S. and Europe.
To the extent that statements contained in the pre-recorded
presentation are not descriptions of historical facts regarding
Clovis Oncology, they are forward-looking statements reflecting the
current beliefs and expectations of management. Examples of
forward-looking statements contained in such presentation include,
among others, statements regarding our expectations for commercial
launches, availability of study data and submission of regulatory
filings. Such forward-looking statements involve substantial risks
and uncertainties that could cause our future results, performance
or achievements to differ significantly from that expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, whether future study results
will support continued development, the timing of availability of
data from our clinical trials, the uncertainties inherent in
actions or decisions by the FDA, the EMA or other regulatory
authorities regarding whether to accept or approve drug
applications that may be filed, including delays or denials of
regulatory approvals, clearances or authorizations for
applications, as well as their decisions regarding drug labeling,
reimbursement and pricing. These forward-looking statements speak
only as of the date hereof. Clovis Oncology does not undertake to
update or revise any forward-looking statements. A further
description of risks and uncertainties can be found in Clovis
Oncology’s filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K and its reports on Form
10-Q and Form 8-K.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201120005171/en/
Anna Sussman 303.625.5022 asussman@clovisoncology.com
Breanna Burkart 303.625.5023 bburkart@clovisoncology.com
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Apr 2023 to Apr 2024